ReviewInternational journal of hematology2009
Iron chelation therapy in the management of thalassemia: the Asian perspectives.
Review in International journal of hematology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Pooled it
- Prevalence of transfusion-transmitted infections in multiple blood transfusion-dependent thalassemic patients in Asia: A systemic review.International journal of immunopathology and pharmacologyPooled it
- Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias.Blood transfusion = Trasfusione del sangue · 2013Trial
- Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox.International journal of hematology · 2011Trial
- Article
- Skin complications during iron chelation therapy for beta-thalassemia: overview and treatment approach.International journal of hematology · 2024Review
- Justification of Universal Iron Supplementation for Infants 6-12 months in Regions with a High Prevalence of Thalassemia.Mediterranean journal of hematology and infectious diseases · 2023Article
- Efficiency and management factors: finding the balance in Thalassaemia care centres.Health economics review · 2022Article
- Effects of green tea extract treatment on erythropoiesis and iron parameters in iron-overloaded β-thalassemic mice.Frontiers in physiology · 2022Article
- Detection of endocrine disorders in young children with multi-transfused thalassemia major.Italian journal of pediatrics · 2021Article
- Feasibility of and barriers to thalassemia screening in migrant populations: a cross-sectional study of Myanmar and Cambodian migrants in Thailand.BMC public health · 2021Article
- Systematic adaptation of the Thai version of the supportive and palliative care indicators tool for low-income setting (SPICT-LIS).BMC palliative care · 2021Article
- A Southeast Asian Perspective on the COVID-19 Pandemic: Hemoglobin E (HbE)-Trait Confers Resistance Against COVID-19.Medical science monitor basic research · 2021Article
- Analysis of determinant factors of liver fibrosis progression in ex-thalassemic patients.International journal of hematology · 2021Observational
- Changing patterns in the epidemiology of β-thalassemia.European journal of haematology · 2020Review
- Article
- Prevalence of Anaemia and Iron Deficiency among Primary Schoolchildren in Malaysia.International journal of environmental research and public health · 2018Article
- A composite mouse model of aplastic anemia complicated with iron overload.Experimental and therapeutic medicine · 2018Article
- Prevalence of Sero-Molecular Markers of Hepatitis C and B Viruses among Patients withThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2018Article
- Epidemiology of Transfusion Transmitted Infection among Patients with β-Thalassaemia Major in Pakistan.Journal of blood transfusion · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Worldwide, thalassemia is the most commonly inherited hemolytic anemia, and it is most prevalent in Asia and the Middle East. Iron overload represents a significant problem in patients with transfusion-dependent beta-thalassemia. Chelation therapy with deferoxamine has traditionally been the standard therapeutic option but its usage is tempered by suboptimal patient compliance due to the discomfort and demands associated with the administration regimen. Therefore, a great deal of attention has been focused on the development of oral chelating agents. Deferiprone, even though available for nearly two decades in Asia with recent encouraging data on cardiac iron removal and long-term efficacy, has serious adverse effects including agranulocytosis and neutropenia which has impeded it from routine clinical practice. A novel oral chelator; deferasirox is effective throughout a 24 h dosing period and both preclinical and clinical data indicate that it successfully removes both hepatic and cardiac iron. In Asia, optimal management of severe thalassemia patients and the availability and access to oral iron chelators still presents a major challenge in many countries. In this regard, the development and implementation of consensus guidelines for management of Asian patients with transfusion-dependent thalassemia will be a major step towards improving and maintaining the continuity of patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.